Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PNT2258 · 3 trials · 6 indications
The proportion of patients with complete response (CR/complete metabolic response \[CMR\]) or partial response (PR/partial metabolic response \[PMR\]) according to the revised 2014 International Working Group (IWG) criteria for lymphoma (Cheson 2014)
Safety and tolerability of PNT2258 and the determination of dose-limiting toxicities (DLTs) and the recommended Phase 2 dose
| Arm | Type | Description |
|---|---|---|
| PNT2258 | EXPERIMENTAL | PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 "induction" cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258. |
| Name | Type | Description |
|---|---|---|
| PNT2258 | DRUG | - |
Inclusion Criteria: Histologically confirmed diffuse large B-cell lymphoma that is refractory to prior therapy or relapsed after prior therapy. FDG PET-CT (disease) positive baseline scan with measurable disease. The patient must have received prior therapy that included: * CD20-targeted therapy...
PNT2258 is an investigational small molecule being studied for the treatment of cancer, including lymphoma, diffuse large B-cell lymphoma, and non-Hodgkin's lymphoma. It has been evaluated in clinical trials for advanced solid tumors and relapsed or refractory lymphomas.
PNT2258 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK.
PNT2258 has completed Phase 1 and Phase 2 clinical trials. It is an investigational drug and has not been approved by regulatory authorities. Its development status is based on completed trials in oncology indications.
PNT2258 has been studied in three completed clinical trials: NCT01191775 in advanced solid tumors, NCT01733238 in relapsed or refractory non-Hodgkin's lymphoma, and NCT02226965 in relapsed or refractory diffuse large B-cell lymphoma. These trials were conducted in the United States and Puerto Rico.
PNT2258 is a distinct investigational small molecule. No alternative names for PNT2258 have been reported in the clinical trial information available.